ArticleAnnals of translational medicine2017
The chicken or the egg dilemma: intestinal dysbiosis in multiple sclerosis.
Article in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function
Single-Arm, Non-Randomized, Time Series, Single-Subject Study: Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome.iScience · 2025Article
- Microbial influences on HPV infection and cervical carcinogenesis: emerging evidence from the vaginal microbiome.Frontiers in microbiology · 2025Review
- Activity of BiocidinFrontiers in antibiotics · 2025Article
- Alterations of Vaginal Microbiota andMicroorganisms · 2023Review
- The role of the microbiota-gut-brain axis in long-term neurodegenerative processes following traumatic brain injury.The European journal of neuroscience · 2023Review
- Intra-Amniotic Administration-An Emerging Method to Investigate Necrotizing Enterocolitis, In Vivo (Nutrients · 2022Article
- Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases.Antibiotics (Basel, Switzerland) · 2022Review
- FecalMetabolites · 2022Article
- Review
- Review
- Oxidative/Nitroxidative Stress and Multiple Sclerosis.Journal of molecular neuroscience : MN · 2021Review
- Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know.Brain sciences · 2020Review
- A Gut Feeling: The Importance of the Intestinal Microbiota in Psychiatric Disorders.Frontiers in immunology · 2020Review
- Article
- Psychological Stress, Intestinal Barrier Dysfunctions, and Autoimmune Disorders: An Overview.Frontiers in immunology · 2020Review
- Synergistic effects of APOE and sex on the gut microbiome of young EFAD transgenic mice.Molecular neurodegeneration · 2019Article
- Oral neonatal antibiotic treatment perturbs gut microbiota and aggravates central nervous system autoimmunity in Dark Agouti rats.Scientific reports · 2019Article
- The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue.Medical sciences (Basel, Switzerland) · 2018Review
- The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.Brain : a journal of neurology · 2018Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent findings suggest that the intestinal microbiota of patients suffering from relapsing remitting multiple sclerosis (MS) shows changes on the relative abundances of archaeal and bacterial genera. Although the richness and overall structure of the microbiota may be similar compared to the intestinal microbiota of healthy controls, elevated and reduced frequencies suggest a dysbiotic microbiota in MS. Over the past decade experimental evidence obtained in murine models of the disease highlighted the important relevance of the microbiota in the regulation of the immune system and in the severity of the disease. More recent findings on peripheral immune cells derived from human MS patients support the initial observations that changes in the microbiota may affect immunological pathways that could exacerbate disease. However, important questions remain to be answered. For instance, it is unclear whether dysbiosis precedes disease or, if in the contrary, an autoimmune disease such as MS can lead to gut dysbiosis. In this brief discussion, we speculate about this later possibility based on findings observed in murine models of disease. Further human studies are needed to answer the dilemma and determine specific immunomodulatory pathways that could have an impact on the therapeutic approaches to treat MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.